Three-dimensional nuclear telomere organization in multiple myeloma

Translational Oncology

Volumn 6, Issue 6, 2013, Pages 749-756

  Klewes, Ludger ^a   Vallente, Rhea ^a   Dupas, Eric ^a   Brand, Carolin ^a,b   Grün, Dietrich ^a,c   Guffei, Amanda ^a   Sathitruangsak, Chirawadee ^a,d   Awe, Julius A ^a   Kuzyk, Alexandra ^a   Lichtensztejn, Daniel ^a   Tammur, Pille ^e   Ilus, Tiiu ^e   Tamm, Anu ^e   Punab, Mari ^e   Rubinger, Morel ^f   Olujohungbe, Adebayo ^f   Mai, Sabine ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c TU DORTMUND UNIVERSITY   (Germany)

^d PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^e TARTU UNIVERSITY HOSPITAL   (Estonia)

^f CANCERCARE MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

SYNDECAN 1;

AGED; ARTICLE; CHROMOSOME ANALYSIS; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; TELOMERE; THREE DIMENSIONAL IMAGING;

EID: 84891688257     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13613     Document Type: Article

References (84)

1. Therneau TM, Kyle RA, Melton LJ III, Larson DR, Benson JT, Colby CL, Dispenzieri A, Kumar S, Katzmann JA, Cerhan JR, et al. (2012). Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc 87, 1071-1079.
2. Kyle RA and Rajkumar SV (2002). Monoclonal gammopathies of undetermined significance. Rev Clin Exp Hematol 6, 225-252.
3. Kyle RA and Rajkumar SV (2008). Multiple myeloma. Blood 111, 2962-2972.
4. Terpos E and Rahemtulla A (2007). Myeloma. In Postgraduate Haematology (5th ed). AV Hoffbrand, D Catovsky, and EGD Tuddenham (Eds). Blackwell Publishing Ltd, Oxford, United Kingdom. pp. 681-702.
5. Jemal A, Siegel R, Ward E, Murray T, Xu J, and Thun MJ (2007). Cancer statistics. CA Cancer J Clin 57, 43-66.
6. http: //seer. cancer. gov/statfacts/html/mulmy. html#incidence-mortality
7. Graham-Rowe D (2011). Overview: multiple lines of attack. Nature 14, S34-S35.
8. Landgren O and Weiss BM (2009). Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 23, 1691-1697.
9. Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, and Trichopoulos D (2007). Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 120, 40-61.
10. Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D, Fears TR, Hoover RN, and Linet MS (2006). Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107, 904-906.
11. Landgren O and Waxman AJ (2010). Multiple myeloma precursor disease. JAMA 304, 2397-2404.
12. Landgren O (2011). Multiple myeloma precursor disease: current clinical dilemma and future opportunities. Semin Hematol 48, 1-3.
13. Kyle RA and Rajkumar SV (2007). Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol 139, 730-743.
14. Steinbrunn T, Stühmer T, Gattenlöhner S, Rosenwald A, Mottok A, Unzicker C, Einsele H, Chatterjee M, and Bargou RC (2011). Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood 117, 1998-2004.
15. Rajkumar SV, Mesa RA, and Tefferi A (2002). A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies. J Hematother Stem Cell Res 11, 33-47.
16. Bergsagel PL and Chesi M (2013). V. Molecular classification and risk stratification of myeloma. Hematol Oncol 31, 38-41.
17. Gadji M, Vallente R, Klewes L, Righolt C, Wark L, Kongruttanachok N, Knecht H, and Mai S (2011). Nuclear remodeling as a mechanism for genomic instability in cancer. Adv Cancer Res 112, 77-126.
18. Chng WC, Glebov O, Bergsagel PL, and Kuehl WM (2007). Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 20, 571-596.
19. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, et al. (2011). Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472.
20. http: //www. themmrf. org/research-programs/commpass-study/#sthash. apOWszeO. dpuf
21. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, et al. (2005). International staging system for multiple myeloma. J Clin Oncol 23, 3412-3420.
22. Durie BG and Salmon SE (1975). A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36, 842-854.
23. Durie BG (2006). The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 42, 1539-1543.
24. Hari PN, Zhang MJ, Roy V, Pérez WS, Bashey A, To LB, Elfenbein G, Freytes CO, Gale RP, Gibson J, et al. (2009). Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia 23, 1528-1534.
25. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, et al. (2010). Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 85, 824-833.
26. Greco A, Tedeschi A, Varettoni M, Nichelatti M, Paris L, Ricci F, Vismara E, and Morra E (2011). Factors predicting transformation of asymptomatic IgM monoclonal gammopathy. Clin Lymphoma Myeloma Leuk 11, 77-79.
27. Pellat-Deceunynck C, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N, Wijdenes J, and Amiot M (1994). Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 84, 2597-2603.
28. Robillard N, Jego G, Pellat-Deceunynck C, Pineau D, Puthier D, Mellerin MP, Barillé S, Rapp MJ, Harousseau JL, Amiot M, et al. (1998). CD28, a marker associated with tumoral expansion in multiple myeloma. Clin Cancer Res 4, 1521-1526.
29. Dahl IM, Rasmussen T, Kauric G, and Husebekk A (2002). Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol 116, 273-277.
30. Pérez-Andres M, Almeida J, Martin-Ayuso M, Moro MJ, Martin-Nuñez G, Galende J, Hernandez J, Mateo G, San Miguel JF, Orfao A, et al. (2006). Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vβ repertoire. Cancer 106, 1296-1305.
31. Pérez-Andrés M, Almeida J, Martín-Ayuso M, Moro MJ, Martin-Nuñez G, Galende J, Borrego D, Rodríguez MJ, Ortega F, Hernandez J, et al. (2005). Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 19, 449-455.
32. San Miguel JF, Gutiérrez NC, Mateo G, and Orfao A (2006). Conventional diagnostics in multiple myeloma. Eur J Cancer 42, 1510-1519.
33. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, et al. (2008). Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 93, 431-438.
34. Pérez-Andrés M, Santiago M, Almeida J, Mateo G, Porwit-MacDonald A, Bjorklund E, Valet G, Kraan J, Gratama JW, D'Hautcourt JL, et al. (2004). Immunophenotypic approach to the identification and characterization of clonal plasma cells from patients with monoclonal gammopathies. J Biol Regul Homeost Agents 18 (3-4), 392-398.
35. Chuang TC, Moshir S, Garini Y, Chuang AY, Young IT, Vermolen B, van den Doel R, Mougey V, Perrin M, Braun M, et al. (2004). The three-dimensional organization of telomeres in the nucleus of mammalian cells. BMC Biol 2, 12.
36. Mai S and Garini Y (2005). Oncogenic remodeling of the three-dimensional organization of the interphase nucleus: c-Myc induces telomeric aggregates whose formation precedes chromosomal rearrangements. Cell Cycle 4, 1327-1331.
37. Mai S and Garini Y (2006). The significance of telomeric aggregates in the interphase nuclei of tumor cells. J Cell Biochem 97, 904-915.
38. Louis SF, Vermolen BJ, Garini Y, Young IT, Guffei A, Lichtensztejn Z, Kuttler F, Chuang TC, Moshir S, Mougey V, et al. (2005). c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. Proc Natl Acad Sci USA 102, 9613-9618.
39. Mai S (2010). Initiation of telomere-mediated chromosomal rearrangements in cancer. J Cell Biochem 109, 1095-1102.
40. Xu L, Li S, and Stohr BA (2013). The role of telomere biology in cancer. Annu Rev Pathol 24, 49-78.
41. Vermolen BJ, Garini Y, Mai S, Mougey V, Fest T, Chuang TC, Chuang AY, Wark L, and Young IT (2005). Characterizing the three-dimensional organization of telomeres. Cytometry A 67, 144-150.
42. Gadji M, Fortin D, Tsanaclis AM, Garini Y, Katzir N, Wienburg Y, Yan J, Klewes L, Klonisch T, Drouin R, et al. (2010). Three-dimensional nuclear telomere architecture is associated with differential time to progression and overall survival in glioblastoma patients. Neoplasia 12, 183-191.
43. Samassekou O, Hébert J, Mai S, and Yan J (2013). Nuclear remodeling of telomeres in chronic myeloid leukemia. Genes Chromosomes Cancer 52, 495-502.
44. Sellmann L, de Beer D, Bartels M, Opalka B, Nückel H, Dührsen U, Dürig J, Seifert M, Siemer D, Küppers R, et al. (2011). Telomeres and prognosis in patients with chronic lymphocytic leukaemia. Int J Hematol 93, 74-82.
45. Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S, Fegan C, Pepper C, and Baird DM (2010). Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood 116, 1899-1907.
46. Ramsay AJ, Quesada V, Foronda M, Conde L, Martínez-Trillos A, Villamor N, Rodríguez D, Kwarciak A, Garabaya C, Gallardo M, et al. (2013). POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet 45, 526-530.
47. Zou YS, Ouahchi K, Lu Y, Liu W, Christensen T, Schappert J, and Saleki R (2012). Jumping translocations of 3q21 in an acute monocytic leukemia (M5) patient reveal mechanisms of multistage telomere shortening in pathogenesis of AML. Leuk Res 36, e31-e33.
48. Gadji M, Adebayo Awe J, Rodrigues P, Kumar R, Houston DS, Klewes L, Dièye TN, Rego EM, Passetto RF, de Oliveira FM, et al. (2012). Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups. Clin Cancer Res 18, 3293-3304.
49. Knecht H, Brüderlein S, Mai S, Möller P, and Sawan B (2010). 3D structural and functional characterization of the transition from Hodgkin to Reed-Sternberg cells. Ann Anat 192, 302-308.
50. Cremer M, Grasser F, Lanctôt C, Müller S, Neusser M, Zinner R, Solovei I, and Cremer T (2008). Multicolor 3D fluorescence in situ hybridization for imaging interphase chromosomes. Methods Mol Biol 463, 205-239.
51. Guffei A, Sarkar R, Klewes L, Righolt C, Knecht H, and Mai S (2010). Dynamic chromosomal rearrangements in Hodgkin's lymphoma are due to ongoing threedimensional nuclear remodeling and breakage-bridge-fusion cycles. Haematologica 95, 2038-2046.
52. Schaefer LH, Schuster D, and Herz H (2001). Generalized approach for accelerated maximum likelihood based image restoration applied to three-dimensional fluorescence microscopy. J Microsc 204, 99-107.
53. Knecht H, Kongruttanachok N, Sawan B, Brossard J, Prévost S, Turcotte E, Lichtensztejn Z, Lichtensztejn D, and Mai S (2012). Three-dimensional telomere signatures of Hodgkin-and Reed-Sternberg cells at diagnosis identify patients with poor response to conventional chemotherapy. Transl Oncol 5, 269-277.
54. Knecht H, Brüderlein S, Wegener S, Lichtensztejn D, Lichtensztejn Z, Lemieux B, Möller P, and Mai S (2010). 3D nuclear organization of telomeres in the Hodgkin cell lines U-HO1 and U-HO1-PTPN1: PTPN1 expression prevents the formation of very short telomeres including "t-stumps". BMC Cell Biol 11, 99.
55. Xu L and Blackburn EH (2007). Human cancer cells harbor T-stumps, a distinct class of extremely short telomeres. Mol Cell 28, 315-327.
56. Wark L, Danescu A, Natarajan S, Zhu X, Cheng SY, Hombach-Klonisch S, Mai S, and Klonisch T (2013). Three-dimensional telomere dynamics in follicular thyroid cancer. Thyroid, E-pub ahead of print September 4.
57. Danescu A, Herrero Gonzalez S, Di Cristofano A, Mai S, and Hombach-Klonisch S (2013). Three-dimensional nuclear telomere architecture changes during endometrial carcinoma development. Genes Chromosomes Cancer 52, 716-732.
58. Adebayo Awe J, Xu MC, Wechsler J, Benali-Furet N, Cayre YE, Saranchuk J, Drachenberg D, and Mai S (2013). Three-dimensional telomeric analysis of isolated circulating tumor cells (CTCs) defines CTC subpopulations. Transl Oncol 6, 51-65.
59. Kuzyk A and Mai S (2013). Selected telomere length changes and aberrant three-dimensional nuclear telomere organization during fast-onset mouse plasmacytomas. Neoplasia 14, 344-351.
60. Guijon FB, Greulich-Bode K, Paraskevas M, Baker P, and Mai S (2007). Premalignant cervical lesions are characterized by dihydrofolate reductase gene amplification and c-Myc overexpression: possible biomarkers. J Low Genit Tract Dis 11, 265-272.
61. Fest T, Guffei A, Williams G, Silva S, and Mai S (2005). Uncoupling of genomic instability and tumorigenesis in a mouse model of Burkitt's lymphoma expressing a conditional box II-deleted Myc protein. Oncogene 24, 2944-2953.
62. Fest T, Mougey V, Dalstein V, Hagerty M, Milette D, Silva S, and Mai S (2002). c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis. Oncogene 21, 2981-2990.
63. Knecht H, Sawan B, Lichtensztejn D, Lemieux B, Wellinger RJ, and Mai S (2009). The 3D nuclear organization of telomeres marks the transition from Hodgkin to Reed-Sternberg cells. Leukemia 23, 565-573.
64. Lovell R, Dunn JA, Begum G, Barth NJ, Plant T, Moss PA, Drayson MT, and Pratt G (2005). Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival. Br J Haematol 130, 542-548.
65. Wijdenes J, Vooijs WC, Clément C, Post J, Morard F, Vita N, Laurent P, Sun RX, Klein B, and Dore JM (1996). A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94, 318-323.
66. Merryweather A (2009). CD138 expression on circulating myeloma cells: disease activity correlation. IBMS Biomedical Sciences Congress Birmingham, UK, 28th-30th September. The Biomedical Scientist. pp. 952-953.
67. Zink D, Fischer AH, and Nickerson JA (2004). Nuclear structure in cancer cells. Nat Rev Cancer 4, 677-687.
68. Jones CH, Pepper C, and Baird DM (2012). Telomere dysfunction and its role in haematological cancer. Br J Haematol 156, 573-587.
69. Gancarcíková M, Zemanová Z, Brezinová J, Berková A, Vcelíková S, Smigová J, and Michalová K (2010). The role of telomeres and telomerase complex in haematological neoplasia: the length of telomeres as a marker of carcinogenesis and prognosis of disease. Prague Med Rep 111, 91-105.
70. Lange K, Holm L, Vang Nielsen K, Hahn A, Hofmann W, Kreipe H, Schlegelberger B, and Göhring G (2010). Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes Chromosomes Cancer 49, 260-269.
71. Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, Jonathan K, Cole AL, Painter JS, Guerrier M, Meléndez-Santiago J, et al. (2011). Telomere length in myelodysplastic syndromes. Leuk Lymphoma 52, 1528-1536.
72. Brugat T, Nguyen-Khac F, Grelier A, Merle-Béral H, and Delic J (2010). Telomere dysfunction-induced foci arise with the onset of telomeric deletions and complex chromosomal aberrations in resistant chronic lymphocytic leukemia cells. Blood 116, 239-249.
73. Mansouri L, Grabowski P, Degerman S, Svenson U, Gunnarsson R, Cahill N, Smedby KE, Geisler C, Juliusson G, Roos G, et al. (2013). Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. Am J Hematol 88, 647-651.
74. Brugat T, Nguyen-Khac F, Merle-Béral H, and Delic J (2011). Concomitant telomere shortening, acquisition of multiple chromosomal aberrations and in vitro resistance to apoptosis in a single case of progressive CLL. Leuk Res 35, e37-e40.
75. Leufke C, Leykauf J, Krunic D, Jauch A, Holtgreve-Grez H, Böhm-Steuer B, Bröcker EB, Mauch C, Utikal J, Hartschuh W, et al. (2013). The telomere profile distinguishes two classes of genetically distinct cutaneous squamous cell carcinomas. Oncogene, E-pub ahead of print August 19.
76. d'Adda di Fagagna F, Teo SH, and Jackson SP (2004). Functional links between telomeres and proteins of the DNA-damage response. Genes Dev 18, 1781-1799.
77. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, and Jackson SP (2003). A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194-198.
78. Pai RB, Pai SB, Yang L, and Joshi HC (2010). Abundance of a distinct cluster of telomere t-stumps in advanced breast cancer cell line. Oncol Lett 1, 339-343.
79. Thiago LS, Perez-Andres M, Balanzategui A, Sarasquete ME, Paiva B, Jara-Acevedo M, Barcena P, Sanchez ML, Almeida J, Gonzalez M, et al. (2013). Circulating clonotypic B-cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica, E-pub ahead of print July 19.
80. Szczepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR, and Pilarski LM (1998). A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 92, 2844-2855.
81. Bergsagel PL, Masellis Smith A, Belch AR, and Pilarski LM (1995). The blood B-cells and bone marrow plasma cells in patients with multiple myeloma share identical IgH rearrangements. Blood 85, 436-447.
82. Magrangeas F, Avet-Loiseau H, Gouraud W, Lodé L, Decaux O, Godmer P, Garderet L, Voillat L, Facon T, Stoppa AM, et al. (2013). Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 27, 473-481.
83. Klewes L, Höbsch C, Katzir N, Rourke D, Garini Y, and Mai S (2011). Novel automated three-dimensional genome scanning based on the nuclear architecture of telomeres. Cytometry A 79, 159-166.
84. Hart AJ, Jagasia MH, Kim AS, Mosse CA, Savani BN, and Kassim A (2012). Minimal residual disease in myeloma: are we there yet? Biol Blood Marrow Transplant 18, 1790-1799.